Infographic
DLL3 Pathology Assessment & Reporting Checklist
09/03/2026
This checklist guides pathologists through practical delta-like ligand 3 (DLL3) assessment and reporting, from confirming neuroendocrine carcinoma diagnosis and specimen adequacy to immunohistochemistry interpretation and scoring. The checklist emphasizes tissue stewardship, assay-specific assessment, distinguishing “DLL3-positive” from “DLL3-high,” documenting testing limitations, and reporting methodology and thresholds clearly to support accurate clinical interpretation and biomarker-directed care.
© 2026 HMP Global. All Rights Reserved.
